American Century Companies Inc. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

American Century Companies Inc. reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.1% during the 4th quarter, HoldingsChannel reports. The fund owned 3,902,432 shares of the biopharmaceutical company’s stock after selling 2,225 shares during the period. American Century Companies Inc.’s holdings in Amicus Therapeutics were worth $36,761,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP raised its holdings in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after buying an additional 2,856,101 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Amicus Therapeutics in the third quarter valued at $13,530,000. Rice Hall James & Associates LLC raised its stake in shares of Amicus Therapeutics by 41.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock valued at $12,916,000 after acquiring an additional 398,942 shares during the period. Old West Investment Management LLC lifted its holdings in shares of Amicus Therapeutics by 617.2% in the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock worth $3,636,000 after acquiring an additional 292,976 shares during the last quarter. Finally, PDT Partners LLC purchased a new position in shares of Amicus Therapeutics during the 3rd quarter worth about $2,702,000.

Amicus Therapeutics Price Performance

FOLD opened at $8.59 on Friday. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of -47.72, a PEG ratio of 1.51 and a beta of 0.69. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 12-month low of $8.40 and a 12-month high of $12.65. The business’s fifty day simple moving average is $9.30 and its 200-day simple moving average is $9.99.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Wells Fargo & Company decreased their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.